Baby Aspirin and Cancer Prevention in Lynch Syndrome: New CaPP3 Results

Professor Sir John Burn joined Dr. Swati Patel at the CGA-IGC 2025 Annual Meeting to share long-awaited results from the CaPP3 trial, a follow-up to the landmark CAPP2 study that first demonstrated aspirin’s ability to reduce cancer risk in people with Lynch syndrome.  While some questions remain unanswered and more research is needed, Sir John Burn discusses the results from the study and the considerations surrounding aspirin as a chemopreventive in Lynch syndrome.